Dolutegravir once daily with rifampicin for HIV and tuberculosis.
作者信息
Naidoo Anushka, Dooley Kelly E
机构信息
Center for the AIDS Program of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Durban 4001, South Africa.
Vanderbilt University Medical Center, Nashville, TN, USA.
出版信息
Lancet HIV. 2023 Jul;10(7):e422-e423. doi: 10.1016/S2352-3018(23)00115-7. Epub 2023 May 22.
Abstract
摘要
相似文献
1
Dolutegravir once daily with rifampicin for HIV and tuberculosis.多替拉韦每日一次与利福平联合用于治疗艾滋病和结核病。
Lancet HIV. 2023 Jul;10(7):e422-e423. doi: 10.1016/S2352-3018(23)00115-7. Epub 2023 May 22.
2
Dosing of Dolutegravir in TB/HIV Coinfected Patients on Rifampicin: Twice Is (Always) Better Than Once.在接受利福平治疗的结核病/艾滋病病毒合并感染患者中多替拉韦的给药剂量：每日两次优于每日一次。
J Acquir Immune Defic Syndr. 2020 Jul 1;84(3):e17-e20. doi: 10.1097/QAI.0000000000002352.
3
Dolutegravir use in combination with rifampicin-based tuberculosis therapy: 3 years of real-world experience in a large UK teaching hospital.多替拉韦与基于利福平的结核病治疗联合使用：英国一家大型教学医院的3年真实世界经验。
Sex Transm Infect. 2018 Sep;94(6):420. doi: 10.1136/sextrans-2018-053698. Epub 2018 Jul 20.
4
Twice-Daily vs. Once-Daily Dolutegravir in Patients With Human Immunodeficiency Virus-Tuberculosis Coinfection Receiving Rifampicin-Based Tuberculosis Therapy.接受基于利福平的抗结核治疗的人类免疫缺陷病毒合并结核感染患者中，每日两次与每日一次多替拉韦的对比研究
Clin Infect Dis. 2020 Jun 24;71(1):242-243. doi: 10.1093/cid/ciz917.
5
Efficacy of dolutegravir + lamivudine q.d. with food in people with TB/HIV using a rifampicin-based regimen: A retrospective observational case series.在使用利福平为基础方案的人群中，每日一次进食时服用多替拉韦 + 拉米夫定治疗结核病/艾滋病的疗效：一项回顾性观察性病例系列研究。
HIV Med. 2024 Jun;25(6):754-758. doi: 10.1111/hiv.13632. Epub 2024 Mar 17.
6
Twice-Daily Dolutegravir-Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis Prevention.每日利福平与异烟肼 1 个月方案用于结核病预防，联合双日服用度鲁特韦的抗逆转录病毒疗法。
Clin Infect Dis. 2024 Oct 15;79(4):983-989. doi: 10.1093/cid/ciae183.
7
Real-world use and outcomes of dolutegravir-containing antiretroviral therapy in HIV and tuberculosis co-infection: a site survey and cohort study in sub-Saharan Africa.在 HIV 和结核病合并感染中使用多替拉韦抗逆转录病毒治疗的真实世界应用和结局：撒哈拉以南非洲的现场调查和队列研究。
J Int AIDS Soc. 2022 Jul;25(7):e25961. doi: 10.1002/jia2.25961.
8
Pharmacokinetics and safety of dolutegravir in children receiving rifampicin tuberculosis treatment in South Africa (ORCHID): a prospective cohort study.多替拉韦在南非接受利福平治疗的结核病儿童中的药代动力学和安全性（兰花研究）：一项前瞻性队列研究。
Lancet HIV. 2025 Apr;12(4):e273-e282. doi: 10.1016/S2352-3018(24)00312-6. Epub 2025 Feb 26.
9
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.多拉韦林每日两次给药治疗儿童 HIV 相关结核病：在开放性标签、多中心、随机、非劣效性 ODYSSEY 试验中的药代动力学和安全性研究。
Lancet HIV. 2022 Sep;9(9):e627-e637. doi: 10.1016/S2352-3018(22)00160-6. Epub 2022 Jul 19.
10
Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 Countries.双倍剂量度鲁特韦在接受基于利福平的结核病治疗的人群中的有效性：一项对来自6个国家的HIV感染者的观察性队列研究。
Clin Infect Dis. 2025 Feb 5;80(1):137-143. doi: 10.1093/cid/ciae269.
引用本文的文献
1
State of the art of real-life concentration monitoring of rifampicin and its implementation contextualized in resource-limited settings: the Tanzanian case.利福平实际浓度监测的技术现状及其在资源有限环境中的实施情况：以坦桑尼亚为例
JAC Antimicrob Resist. 2024 Nov 14;6(6):dlae182. doi: 10.1093/jacamr/dlae182. eCollection 2024 Dec.
2
Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 Countries.双倍剂量度鲁特韦在接受基于利福平的结核病治疗的人群中的有效性：一项对来自6个国家的HIV感染者的观察性队列研究。
Clin Infect Dis. 2025 Feb 5;80(1):137-143. doi: 10.1093/cid/ciae269.
3
Advances in Antiretroviral Therapy for Patients with Human Immunodeficiency Virus-Associated Tuberculosis.人类免疫缺陷病毒相关结核病患者抗逆转录病毒治疗的进展
Viruses. 2024 Mar 23;16(4):494. doi: 10.3390/v16040494.
本文引用的文献
1
Clinical and Virological Outcomes of TB/HIV Coinfected Patients Treated With Dolutegravir-Based HIV Antiretroviral Regimens: Programmatic Experience From Botswana.多替拉韦为基础的抗反转录病毒治疗方案治疗结核/艾滋病毒合并感染患者的临床和病毒学结局：来自博茨瓦纳的规划经验。
J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):111-115. doi: 10.1097/QAI.0000000000002126.
2
Stock-outs of antiretroviral and tuberculosis medicines in South Africa: A national cross-sectional survey.南非抗逆转录病毒和结核病药物缺货情况：全国横断面调查。
PLoS One. 2019 Mar 12;14(3):e0212405. doi: 10.1371/journal.pone.0212405. eCollection 2019.
3
Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes.多替拉韦（S/GSK1349572）与拉替拉韦和艾维雷格韦相比，从野生型和整合酶抑制剂耐药的 HIV-1 整合酶-DNA 复合物中缓慢解离。
Antimicrob Agents Chemother. 2011 Oct;55(10):4552-9. doi: 10.1128/AAC.00157-11. Epub 2011 Aug 1.
4
Factors affecting adherence to antiretroviral therapy.影响抗逆转录病毒疗法依从性的因素。
Clin Infect Dis. 2000 Jun;30 Suppl 2:S171-6. doi: 10.1086/313849.
Zotero 插件